Vincent Matozzo
SCWorxAbout Vincent Matozzo
Vincent Matozzo is an independent director of SCWorx Corp (WORX) with deep supply chain and procurement expertise across healthcare, aerospace, and manufacturing, including roles at Yale New Haven Health, Vizient, and NYU Langone Health (age 41) . He has served as CEO and Managing Partner of Paradigm Venture Group since 2020, focusing on process automation, Lean/Agile modeling, and data visualization in procurement and reimbursement workflows . He was appointed to the SCWorx Board on August 17, 2023 and designated independent per SEC and Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Yale New Haven Health | Director of Strategic Sourcing and Procurement Operations | 2019–2021 | Led procurement operations; Lean/Agile process modeling . |
| Vizient | Supply chain leadership roles | Not disclosed | Digital supply chain and analytics exposure referenced in bio . |
| NYU Langone Health | Supply chain roles | Not disclosed | Procurement and operations experience . |
| Manufacturing/Aerospace (various) | Supply chain capacities | Not disclosed | Broad sector exposure; automation focus . |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Paradigm Venture Group | CEO & Managing Partner | 2020–present | Focus on automating processes, business model innovation, and interoperability improvements . |
Board Governance
- Independence: The Board has determined Matozzo is “independent” under SEC and Nasdaq rules .
- Committees: Compensation Committee member; Audit Committee member; Nominating & Corporate Governance Committee member and Chair .
- Attendance: In fiscal 2024, each director attended all Board and applicable committee meetings during their service; Board met 7 times with 4 consents; Audit met 4 times; Compensation met once; Nominating & Governance met once .
- Leadership: Board Chair is Troy Kirchenbauer; CEO is Timothy Hannibal; CFO is Chris Kohler; no lead independent director disclosed .
- Risk oversight: Board and committees oversee strategic, operational, financial, legal/regulatory risks; Board has not adopted anti‑hedging/derivatives policies for employees or directors, which is a governance weakness .
Fixed Compensation
| Component | 2023 | 2024 |
|---|---|---|
| Annual cash retainer ($) | $0 | $0 |
| Committee membership fees ($) | $0 | $0 |
| Committee chair fees ($) | $0 | $0 |
| Meeting fees ($) | $0 | $0 |
| Expense reimbursement | Reasonable travel/out‑of‑pocket reimbursed | Reasonable travel/out‑of‑pocket reimbursed |
Directors received no cash or equity compensation in 2023–2024, aside from expense reimbursement; Board may award special remuneration for special services .
Performance Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| RSU status (shares) | No securities beneficially owned at appointment (Form 3) | Returned/cancelled 3,056 RSUs; post‑transaction beneficial ownership 0 (Form 4, 5/15/2024) |
On May 15, 2024, Matozzo voluntarily returned and canceled previously granted RSUs issued as director compensation (3,056 shares); resulting beneficial ownership was 0 .
Other Directorships & Interlocks
- Current public company boards: None disclosed beyond SCWorx .
- Prior public company boards: None disclosed in SCWorx filings .
- Nonprofit/academic boards: Not disclosed .
- Interlocks: No committee interlocks or shared directorships with SCWorx competitors/suppliers disclosed .
Expertise & Qualifications
- Lean and Agile process modeling; procurement lifecycle from pre‑award modeling to post‑award monitoring; requisitioning to reimbursement .
- Technical execution and supply chain innovation; data visualization; healthcare supply chain organizational development and business continuity .
- Featured speaker on supply chain organizational development; designs innovative business models for operational results .
Equity Ownership
| Date | Common Shares Beneficially Owned | Notes |
|---|---|---|
| March 31, 2025 | 0 shares; <1% ownership | Company beneficial ownership table shows 0 for Matozzo. |
| October 10, 2025 | 0 shares; <1% ownership | Company beneficial ownership table shows 0 for Matozzo. |
Shares pledged as collateral: Not disclosed; no pledging indicated .
Options/warrants: None disclosed; 0 reported .
Ownership guidelines: Not disclosed in proxy .
Insider Trades
| Item | 2023-08-17 | 2024-05-15 |
|---|---|---|
| Filing | Form 3 (initial ownership) | Form 4 (RSU return/cancel) |
| Security | N/A (no securities) | Restricted Stock Units |
| Shares | 0 | 3,056 returned (D); price $0; post‑transaction 0 |
Governance Assessment
- Committee efficacy: As Chair of Nominating & Corporate Governance, Matozzo leads board composition, succession planning, and governance standards—critical for a small‑cap issuer navigating financing and dilution proposals; 2024 committee work was active with one Nom/Gov meeting and robust Board attendance .
- Independence & alignment: Independent director with zero current beneficial ownership; voluntary RSU return suggests sensitivity to shareholder dilution and alignment concerns during capital raises .
- Compensation: No director cash or equity compensation in 2023–2024, limiting potential pay‑driven conflicts; only expense reimbursement .
- Conflicts/related party: No related‑party transactions disclosed involving Matozzo; company‑level related amounts involved officers/CFO advances, not directors broadly .
- RED FLAGS: Absence of an anti‑hedging policy for employees/directors is a governance gap; the company seeks multiple approvals for substantial below‑minimum‑price issuances and share authorization increases, elevating dilution risk (board‑level issue rather than Matozzo‑specific) .
Tenure and engagement: Appointed August 17, 2023; 100% attendance in 2024 on Board and committee meetings during his service indicates solid engagement .
Overall: Matozzo brings relevant healthcare supply chain and procurement expertise and chairs Nom/Gov, with strong meeting attendance and no identifiable conflicts. The voluntary RSU return is a constructive signal for investor alignment amid capital structure changes; continued focus on governance policies (e.g., anti‑hedging) would strengthen board effectiveness and investor confidence .